| Product | Clinical Indication | Phase of Development | Partner | Anticipated Newsflow |
| Prevascar | Reduction of skin scarring | Phase 2 | - | H1 2012 Proof of concept clinical trial in African subjects reports final data. |
| Juvidex | Improve skin appearance and promote healing of damaged skin | Cosmetic ingredient | - |
Prevascar (an intradermal injectable solution of human recombinant Interleukin 10) previously reported a positive exploratory efficacy trial for the reduction of scarring in the skin. Following improvements in the manufacturing of Prevascar drug substance and product, and identification of a clinical cohort who are predicted (on the basis of a non-drug experimental surgery study) to benefit particularly well from Prevascar's modulating effect on the wound inflammatory response, Renovo has commenced a new proof of concept clinical trial in skin excisions and excisions in African-ancestral group human volunteers and is due to report final data in H1 2012.
Juvidex (topical application of Mannose-6-Phosphate (M-6-P)) reported statistically significant improvements in pre-specified endpoints of skin appearance and acceleration of healing in a proof of concept clinical trial. Renovo intends to sell the Juvidex programme to a partner from the cosmetic industry.
Printer-friendly version